Sex differences in psychotomimetic-induced behaviours in rats

Gogos, Andrea; Kusljic, Snezana; Thwaites, Shane J.; Buuse, Maarten van den

doi:10.1016/j.bbr.2017.01.028

Cited by 13 publications

(11 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prepulse inhibition of startle (PPI), the reduction of startle produced by a prepulse stimulus, is diminished in patients with SCZ and can be easily modeled in animals (Swerdlow and Geyer, 1998 ). Female rats exhibit higher levels of PPI compared to males at baseline (Nozari et al, 2015 ; Zhang X. et al, 2015 ; Gogos et al, 2017 ). NMDA receptor antagonist, MK-801, decreases PPI in both intact and gonadectomized male mice whereas female mice only exhibit this decrease following ovariectomy (van den Buuse et al, 2017 ).…”

Section: Sex Differences In Glutamate Systems In Diseasementioning

confidence: 99%

Sex Differences in Psychiatric Disease: A Focus on the Glutamate System

Wickens

Bangasser

Briand

2018

Front. Mol. Neurosci.

View full text Add to dashboard Cite

Alterations in glutamate, the primary excitatory neurotransmitter in the brain, are implicated in several psychiatric diseases. Many of these psychiatric diseases display epidemiological sex differences, with either males or females exhibiting different symptoms or disease prevalence. However, little work has considered the interaction of disrupted glutamatergic transmission and sex on disease states. This review describes the clinical and preclinical evidence for these sex differences with a focus on two conditions that are more prevalent in women: Alzheimer's disease and major depressive disorder, and three conditions that are more prevalent in men: schizophrenia, autism spectrum disorder, and attention deficit hyperactivity disorder. These studies reveal sex differences at multiple levels in the glutamate system including metabolic markers, receptor levels, genetic interactions, and therapeutic responses to glutamatergic drugs. Our survey of the current literature revealed a considerable need for more evaluations of sex differences in future studies examining the role of the glutamate system in psychiatric disease. Gaining a more thorough understanding of how sex differences in the glutamate system contribute to psychiatric disease could provide novel avenues for the development of sex-specific pharmacotherapies.

show abstract

Section: Sex Differences In Glutamate Systems In Diseasementioning

confidence: 99%

Sex Differences in Psychiatric Disease: A Focus on the Glutamate System

Wickens

Bangasser

Briand

2018

Front. Mol. Neurosci.

View full text Add to dashboard Cite

show abstract

“…With respect to psychosis, animal models of this mental disorder have become increasingly important, attempting to develop specific pharmacological options for this psychiatric condition. Although several reliable animal models of psychosis are actually available and largely used in neuropsychiatric research, mainly based on pharmacologic, genetic, environmental, and neurochemical manipulations, no rodent models which specifically mimic the peculiarities of first psychotic episode in humans have been developed yet. Indeed, so far, progress in the understanding of the molecular pathways underlying this specific phase of the psychotic disorder has been based on the use of animal models only partially reproducing the neuropathological events occurring during the prenatal, perinatal, and juvenile stages of CNS development .…”

Section: Animal Models Of First Psychotic Episode: An Existing Tool?mentioning

confidence: 99%

The use of antioxidant compounds in the treatment of first psychotic episode: Highlights from preclinical studies

Schiavone

Trabace

2018

CNS Neurosci Ther

View full text Add to dashboard Cite

Recent evidence highlighted a pathogenetic link between redox dysregulation and the early stages of psychosis. Indeed, an increasing number of studies have pointed toward an association between oxidative stress, both at central and peripheral levels, and first psychotic episode. Moreover, basal low antioxidant capacity has been shown to directly correlate with cognitive impairment in the early onset of psychosis. In this context, the possibility to use antioxidant compounds in first psychotic episode, especially as supplementation to antipsychotic therapy, has become the focus of numerous investigations on rodents with the aim to translate data on the possible effects of antioxidant therapies to large populations of patients, with a diagnosis of the first psychotic episode. In this review, we will discuss studies, published from January 1st, 2007 to July 31st, 2017, investigating the effects of antioxidant compounds on neuropathological alterations observed in different rodent models characterized by a cluster of psychotic-like symptoms reminiscent of what observed in human first psychotic episode. A final focus on the effective possibility to directly translate data obtained on rodents to humans will be also provided.

show abstract

“…Two of the most widely used assays of psychosis-like behaviour in rodents are disruption of prepulse inhibition of the acoustic startle response (PPI) and psychotomimetic drug-induced locomotor hyperactivity [ 24 , 25 ]. PPI is a cross-species measure of sensorimotor gating and deficits in PPI are present in patients with schizophrenia including untreated patients, and those treated with typical antipsychotics [ 26 , 27 ].…”

Section: Introductionmentioning

confidence: 99%

“…Experimental animals exhibit PPI deficits following treatment with dopamine receptor agonists [ 28 ]. Psychotomimetic drug-induced locomotor hyperactivity is a behavioural test used to model the brain mechanisms involved in psychosis, particularly psychotic agitation/excitement [ 24 , 25 ].…”

Section: Introductionmentioning

confidence: 99%

The effect of estrogenic compounds on psychosis-like behaviour in female rats

2018

Self Cite

View full text Add to dashboard Cite

17β-estradiol treatment has shown benefit against schizophrenia symptoms, however long-term use may be associated with negative side-effects. Selective estrogen receptor modulators, such as raloxifene and tamoxifen, have been proposed as suitable alternatives to 17β-estradiol. An isomer of 17β-estradiol, 17α-estradiol, is considered less carcinogenic, and non-feminising in males, however little is known about its potential as a treatment for schizophrenia. Moreover, the mechanism underlying the therapeutic action of estrogens remains unclear. We aimed to investigate the ability of these estrogenic compounds to attenuate psychosis-like behaviour in rats. We used two acute pharmacologically-induced assays of psychosis-like behaviour: psychotomimetic drug-induced hyperlocomotion and disruption of prepulse inhibition (PPI). Female Long Evans rats were either intact, ovariectomised (OVX), or OVX and chronically treated with 17β-estradiol, 17α-estradiol, raloxifene or tamoxifen. Only 17β-estradiol treatment attenuated locomotor hyperactivity induced by the indirect dopamine receptor agonist, methamphetamine. 17β-estradiol- and tamoxifen-treated rats showed attenuated methamphetamine- and apomorphine (dopamine D1/D2 receptor agonist)-induced disruption of PPI. Raloxifene-treated rats showed attenuated apomorphine-induced PPI disruption only. Baseline PPI was significantly reduced following OVX, and this deficit was reversed by all estrogenic compounds. Further, PPI in OVX rats was increased following administration of apomorphine. This study confirms a protective effect of 17β-estradiol in two established animal models of psychosis, while tamoxifen showed beneficial effects against PPI disruption. In contrast, 17α-estradiol and raloxifene showed little effect on dopamine receptor-mediated psychosis-like behaviours. This study highlights the utility of some estrogenic compounds to attenuate psychosis-like behaviour in rats, supporting the notion that estrogens have therapeutic potential for psychotic disorders.

show abstract

Sex differences in psychotomimetic-induced behaviours in rats

Cited by 13 publications

References 72 publications

Sex Differences in Psychiatric Disease: A Focus on the Glutamate System

Sex Differences in Psychiatric Disease: A Focus on the Glutamate System

The use of antioxidant compounds in the treatment of first psychotic episode: Highlights from preclinical studies

The effect of estrogenic compounds on psychosis-like behaviour in female rats

Contact Info

Product

Resources

About